ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Are they going Private?

<< Previous

Bullboard Posts

Next >>

Comment by bball67on Sep 01, 2024 7:01pm

157 Views

Post# 36204878

RE:Are they going Private?

Brilliant post, they actually file after the market is closed like 100% of the listed companies do. Going private, no reason to do that. The NASDAQ market is just fine. You bring up the topic of going private, what is your reasoning or evidence? I

<< Previous

Bullboard Posts

Next >>

Pro Women’s Hockey League comes to NHL 25 in December